Stock Movers: Intuit, Crowdstrike, Moderna (Podcast)

Intuit shares fell about 3% ahead of earnings, while CrowdStrike faces downward pressure with analysts expecting Q2 revenue of $1.44B and EPS of $0.29, with investors focused on net new ARR growth and AI-security demand. Moderna is up following Wolfe Research’s upgrade to peerperform from underperform, citing success in its melanoma vaccine trial.

Analysis

CRWD is the cleanest read-through: the stock is trading like a durability asset, so the risk is not the quarter itself but any hint that AI-security demand is merely additive rather than budget-share taking. If net new ARR or forward commentary softens, the multiple can compress faster than the revenue miss would imply, with 10-15% downside plausible over days to weeks and spillover risk to PANW, ZS, and the broader software basket. The reverse is also true: an upside guide that confirms acceleration can re-rate the entire cybersecurity cohort because investors are still underpaying for operating leverage in this category.

INTU is a lower-beta earnings event, but the setup is similar in one respect: the market is paying for software-like recurring growth, so any sign that AI-driven productivity is not translating into higher take rate or better retention would pressure the multiple rather than the current-year EPS. The near-term move is likely driven by guidance quality, not the headline beat/miss; if management merely meets, the stock can still fade on de-risking. A durable upside surprise would need evidence that small-business and consumer tax workflows are expanding TAM, not just improving margins.

MRNA looks more interesting structurally, but the market may be extrapolating a clinical signal into a business model revaluation too early. The real catalyst is not the analyst upgrade; it is whether this result can be translated into a credible commercial and regulatory path that changes long-duration cash burn expectations. If follow-through data are weak or timelines slip, the move should mean-revert; if validated, it could support a multi-month rerating of the platform and hurt short-biased sentiment across the vaccine/oncology complex.

Key Decisions for Investors

• CRWD: avoid pre-earnings directional exposure; if the stock rallies on a guide that does not clearly re-accelerate ARR, buy 1-2 month 5%-10% OTM puts or short on the first failed post-print hold. Falsifier: sustained guide raise and net new ARR acceleration.
• CRWD vs PANW/ZS: if CRWD prints merely in-line, use it as a relative-value short versus a stronger-duration peer or basket short in cybersecurity. Target 1-3 month multiple compression of 1-2 turns if growth quality appears to plateau.
• INTU: stay neutral into earnings; only buy a dip if management confirms pricing power and AI automation lifts FY guidance. If the stock rallies but guidance is only consistent, fade the move with a tight stop at the pre-print high.
• MRNA: small tactical long via call spread or starter long for 1-3 month optionality; upside is a rerating on validated oncology read-through, but size must reflect binary clinical risk. Falsifier: weak follow-up data, slower regulatory path, or cash burn commentary that offsets trial optimism.